Valuation : OliX Pharmaceuticals, Inc

Market Cap 2,302B 1.72B 1.48B 1.4B 1.27B 2.38B 164B 2.39B 16.64B 6.4B 83.48B 6.45B 6.31B 264B P/E 2026 *
-70.6x
P/E 2027 * -72.6x
Enterprise Value 2,302B 1.72B 1.48B 1.4B 1.27B 2.38B 164B 2.39B 16.64B 6.4B 83.48B 6.45B 6.31B 264B EV / Sales 2026 *
288x
EV / Sales 2027 * 209x
Free-Float
83.34%
Yield 2026 *
-
Yield 2027 * -
08-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-30 OliX Pharmaceuticals, Inc Reports Preclinical Data Demonstrating Greater Visceral Fat Reduction with Olx501a Versus Global Comparator in Obese Non-Human Primates CI
07-08 OliX Pharmaceuticals, Inc announced that it has received KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-28 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-04 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-31 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-15 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
03-16 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-07 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
12-01 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
11-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-27 OliX Pharmaceuticals, Inc announced that it has received KRW 115.002040047 billion in funding from a group of investors CI
1 day+9.52%
1 week+19.06%
Current month+5.71%
1 month-20.68%
3 months-11.28%
6 months-41.30%
Current year-22.15%
1 week 92,600
Extreme 92600
110,200
1 month 91,200
Extreme 91200
129,800
Current year 86,600
Extreme 86600
217,000
1 year 81,000
Extreme 81000
217,000
3 years 8,280
Extreme 8280
217,000
5 years 8,280
Extreme 8280
217,000
10 years 8,280
Extreme 8280
217,000
Manager TitleAgeSince
Chief Executive Officer 54 2010-01-31
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 2022-03-27
Director TitleAgeSince
Director/Board Member 61 2019-03-18
Director/Board Member 55 2019-03-18
Chairman 54 2010-01-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/28/25 Exercice

Director

30,000 0.1625%
2/28/25 Exercice

Chief Technology Officer

8,000 0.0433%
Change 5-day change 1-year change 3-year change Capi.($)
+9.52%+19.06%+23.50%+336.33% 1.56B
-2.11%-3.44%+41.04%+98.48% 68.24B
-0.23%-6.42%+30.19%+76.15% 62.23B
+1.67%+2.16%-11.32%+392.80% 27.8B
-1.05%-7.30%+25.00%+12.31% 24.86B
+0.34%-5.98%-4.23%-19.48% 24.22B
+0.43%-4.78%+18.26%-20.61% 19.36B
-3.03%-5.19%+192.88%+340.13% 17.28B
-1.94%-6.36%-7.05%+516.16% 14.46B
-2.28%-5.09%+48.86%+153.82% 14.23B
Average +0.13%-2.35%+35.71%+188.61% 27.42B
Weighted average by Cap. -0.80%-3.71%+33.55%+138.09%

Financials

2026 *2027 *
Net sales 8B 5.97M 5.14M 4.87M 4.41M 8.28M 570M 8.32M 57.83M 22.24M 290M 22.41M 21.92M 917M 11B 8.21M 7.07M 6.69M 6.07M 11.38M 784M 11.44M 79.51M 30.58M 399M 30.82M 30.14M 1.26B
Net income -31B -23.13M -19.93M -18.87M -17.1M -32.08M -2.21B -32.25M -224M -86.17M -1.12B -86.85M -84.95M -3.55B -30B -22.38M -19.28M -18.26M -16.55M -31.05M -2.14B -31.21M -217M -83.39M -1.09B -84.05M -82.21M -3.44B
Net Debt - -
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
-
Date Price Change Volume
26-09-11 ₩109,300.00 +9.52% 463,715
26-09-10 ₩99,800.00 +0.60% 248,261
26-09-09 ₩99,200.00 +0.10% 114,519
26-09-08 ₩99,100.00 +1.64% 182,783
26-09-07 ₩97,500.00 +1.67% 135,951
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A226950 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!